DelveInsight’s “Tourette Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tourette Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Tourette Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Tourette Syndrome: An Overview
Tourette Syndrome (TS) or Tourette disorder is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Tics are sudden twitches, movements, or sounds that people do repeatedly. They can be of two types—motor and vocal. Of these, motor tics are movements of the body such as blinking or jerking an arm, whereas vocal tics are sounds that a person makes with his or her voice such as humming. Motor tics generally precede the development of vocal tics, and simple tics often precede complex tics.
Tics come and go over time, varying in type, frequency, location, and severity. The early symptoms of TS are typically noticed first in childhood, with the average onset between the ages of 3 and 9 years. The first symptoms usually occur in the head and neck area and may progress to include muscles of the trunk and extremities.
Tourette Syndrome Market Key Facts
-
A study titled “Meta-analysis:Adulthood prevalence of Tourette syndrome” conducted by Levine et al. (2019), estimated 0.30–0.77% prevalence of TS in school-aged children. Additionally, the study also estimated the overall prevalence in adulthood to be 118 cases per million (95%CI: 19–751 cases per million adults).
-
A report by National Institute For Health Research (NHS), in 2016 stated that TS occurs worldwide and in different cultures. Boys and men are more commonly affected, with the male-to-female ratio between three and four to one.
-
Tourette Association of America reported that Tics occur in as many as 1 in 5 school-aged children at some point, but may not persist. Additionally, the organization suggested that the combined estimate of the occurrence of TS and other Tic Disorders is more than 1 in 100 (1%) school-aged children in the US.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Tourette Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Tourette Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Tourette Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Tourette Syndrome Epidemiology, Segmented as –
-
Prevalent Population of Tourette Syndrome (TS) in the 7MM (2019–2032)
-
Age-specific Prevalent Population of Tourette Syndrome (TS) in the 7MM (2019–2032)
-
Gender-specific Prevalent Population of Tourette Syndrome (TS) in the 7MM (2019–2032)
-
Diagnosed and Treatable Cases of Tourette Syndrome (TS) in the 7MM (2019–2032)
Tourette Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Tourette Syndrome market or expected to be launched during the study period. The analysis covers the Tourette Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Tourette Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Tourette Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/tourette-syndrome-market
Tourette Syndrome Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Tourette syndrome. Currently, Emalex Biosciences is leading the therapeutics market with its Tourette syndrome drug candidates in the most advanced stage of clinical development.
Leading Players in the Tourette Syndrome Therapeutics Market Include
-
Emalex Biosciences
-
Noema Pharma
-
Asarina Pharma
-
Teva Pharmaceutical
-
SciSparc
-
EuMentis Therapeutics
-
Synendos Therapeutics
And Many Others
Tourette Syndrome Emerging and Marketed Drugs Covered in the Report Include:
-
Ecopipam: Emalex Biosciences
-
SCI-110: SciSparc
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/tourette-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Tourette Syndrome Competitive Intelligence Analysis
4. Tourette Syndrome Market Overview at a Glance
5. Tourette Syndrome Disease Background and Overview
6. Tourette Syndrome Patient Journey
7. Tourette Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Tourette Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Tourette Syndrome Unmet Needs
10. Key Endpoints of Tourette Syndrome Treatment
11. Tourette Syndrome Marketed Products
12. Tourette Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Tourette Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Tourette Syndrome Market Outlook (In US, EU5, and Japan)
16. Tourette Syndrome Access and Reimbursement Overview
17. KOL Views on the Tourette Syndrome Market
18. Tourette Syndrome Market Drivers
19. Tourette Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/tourette-syndrome-market
Other Trending Healthcare Reports by DelveInsight
“Tendonitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tendonitis market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Tendonitis market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/